National Comprehensive Cancer Network

Educational Events & Programs

OVERVIEW

As Congress considers revisiting the landmark 21st Century Cures Act, NCCN is engaging experts and gathering perspectives on the successes and challenges of the legislation and its impact on the oncology ecosystem. The June Summit will be conducted as a live webinar and will feature a diverse group of experts who will explore the impact of the 21st Century Cures Act on patients’ access to high-quality cancer care, the implementation of the Cures Act to date, remaining gaps and challenges of the legislation, and a prospective look at Cures 2.0.

AGENDA

Welcome and Introductions

Robert W. Carlson, MD
Chief Executive Officer, National Comprehensive Cancer Network

Policy Recommendations from NCCN Working Group

Jeff Allen, PhD
President & CEO, Friends of Cancer Research

Ronald S. Walters, MD, MBA, MHA, MS
Associate Head for the Institute for Cancer Care Innovation
The University of Texas MD Anderson Cancer Center

Accelerating Access to Innovation and Advancing Patient Centric Cancer Care: A Discussion with Amy Abernethy, MD, PhD
Principal Deputy Commissioner of Food and Drugs, Office of the Commissioner,
The Food and Drug Administration

Moderated by Clifford Goodman, PhD,
The Lewin Group

The Impact of Advancements in Health Information Technology and Interoperability on Patient Access to Information

Don Rucker, MD, MBA, MS
National Coordinator for Health Information Technology,
Office of the National Coordinator for Health IT

Panel Discussion: The Effect of the 21st Century Cures Act on Oncology and Opportunities to Advance Accessible Cancer Care

Moderated by Clifford Goodman, PhD
The Lewin Group

Panelists
Jenny Ahlstrom
Founder, CrowdCare Foundation and Multiple Myeloma Patient

Clay Alspach, JD
Principal, Leavitt Partners

Anobel Odisho, MD, MPH Urologist
UCSF Helen Diller Family Comprehensive Cancer Center and
Clinical Informatics Lead, UCSF Center for Digital Health Innovation

Susan Stiles, MHA, MBA, FACHE
Executive, Oncology Business Unit, Cerner Corporation

A Conversation Discussing the Future of 21st Century Cures A Conversation with Congresswoman Diana DeGette (D-CO) and Congressman Fred Upton (R-MI)

Moderated by Clifford Goodman, PhD
The Lewin Group

Wrap-up and Conclusions

Jeff Allen, PhD
President & CEO, Friends of Cancer Research

Ronald S. Walters, MD, MBA, MHA, MS
Associate Head for the Institute for Cancer Care Innovation,
The University of Texas MD Anderson Cancer Center

SUPPORTERS

Supported by Adaptive, AmerisourceBergen, Amgen, Astellas, AstraZeneca through its NCCN Corporate Council Membership, BeiGene, Ltd., bluebird bio, Dendreon Pharmaceuticals, Eisai Inc, EMD Serono, Exelixis, Foundation Medicine, Inc., Genentech, GSK, Halozyme, Heron, Incyte Corporation, Janssen Oncology; Pharmaceutical Companies of Johnson & Johnson, Kite, a Gilead Company, an independent educational grant from Merck & Co., Inc., MorphoSys US, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharma Oncology, Takeda, and Verastem Oncology. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. This activity was made possible by Pharmacyclics, an AbbVie Company.

As of April 27, 2020.

Access the Library of White Papers!

NCCN offers a broad library of white papers from previous summits that may be pertinent to your organization.

View Supporter Opportunities.